Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training
Multiparametric assays for risk stratification are widely used in the management of breast cancer, with applications being developed for a number of other cancer settings. Recent data from multiple sources suggests that different tests may provide different risk estimates at the individual patient l...
Saved in:
Published in | PloS one Vol. 15; no. 9; p. e0238593 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
San Francisco
Public Library of Science
03.09.2020
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Multiparametric assays for risk stratification are widely used in the management of breast cancer, with applications being developed for a number of other cancer settings. Recent data from multiple sources suggests that different tests may provide different risk estimates at the individual patient level. There is an increasing need for robust methods to support cost effective comparisons of test performance in multiple settings. The derivation of similar risk classifications using genes comprising the following multi-parametric tests Oncotype DX® (Genomic Health.), Prosigna™ (NanoString Technologies, Inc.), MammaPrint® (Agendia Inc.) was performed using different computational approaches. Results were compared to the actual test results. Two widely used approaches were applied, firstly computational “modelling” of test results using published algorithms and secondly a “training” approach which used reference results from the commercially supplied tests. We demonstrate the potential for errors to arise when using a “modelling” approach without reference to real world test results. Simultaneously we show that a “training” approach can provide a highly cost-effective solution to the development of real-world comparisons between different multigene signatures. Comparisons between existing multiparametric tests is challenging, and evidence on discordance between tests in risk stratification presents further dilemmas. We present an approach, modelled in breast cancer, which can provide health care providers and researchers with the potential to perform robust and meaningful comparisons between multigene tests in a cost-effective manner. We demonstrate that whilst viable estimates of gene signatures can be derived from modelling approaches, in our study using a training approach allowed a close approximation to true signature results. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Membership of the OPTIMA Trial Management Group is provided in the Acknowledgments. Current address: Department of Human Genetics & Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, United States of America Competing Interests: JMSB reports consultancies from Insight Genetics, BioNTech AG, Biotheranostics, Pfizer, RNA Diagnostics and oncoXchange, honoraria from NanoString Technologies, Oncology Education and Biotheranostics, travel and accommodation expenses from Biotheranostics and NanoString Technologies, research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technoloiges, Stratifyer GmbH and Biotheranostics, a disclosure “A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer” (Aug 2019), and applied for patents, including: “Methods and Devices for Predicting Anthracycline Treatment Efficacy”, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned (Jan 2017); “Systems, Devices and Methods for Constructing and Using a Biomarker”, US utility – 15/328,108; EPO –15824751.0; Canada – not yet assigned (Jan 2017); “Histone gene module predicts anthracycline benefit”, PCT/CA2016/000247 (Oct 2016); “Immune Gene Signature Predicts Anthracycline Benefit”, PCT/CA2016/000305 (Dec 2016). JMSB, JB, CQY and PCB are co-inventors on the applied for patent: “95-Gene Signature of Residual Risk Following Endocrine Treatment”, PCT/CA2016/000304 (Dec 2016). PD is an employee and shareholder of NanoString Technologies. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials. The remaining authors do not declare any other competing interests. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0238593 |